Does tirzepatide work better than Wegovy for weight loss?
Yes. SURMOUNT-5 tested tirzepatide vs. semaglutide 2.4 mg head-to-head over 72 weeks. Tirzepatide won by a meaningful margin. Here's the data.
Updated June 1, 2026 · 4 min read
Yes — tirzepatide (Zepbound) outperforms semaglutide 2.4 mg (Wegovy) for weight loss. The margin isn't trivial, and it comes from a real head-to-head randomized controlled trial rather than cross-trial comparisons, which had been the only available evidence for years.
SURMOUNT-5: The Head-to-Head Trial
For most of tirzepatide's commercial life, the comparison with semaglutide was indirect. SURMOUNT-1 and STEP-1 each tested their drug against placebo — comparing the two trials meant comparing two different populations, different baseline weights, and different follow-up protocols. SURMOUNT-5 closed that gap.
SURMOUNT-5 was a randomized, double-blind, active-controlled trial comparing tirzepatide (10 mg or 15 mg) directly against semaglutide 2.4 mg in adults with obesity or overweight but without type 2 diabetes. The primary endpoint was percentage change in body weight over 72 weeks.
Tirzepatide produced significantly greater weight loss than semaglutide 2.4 mg. The difference was clinically meaningful — not a rounding error. Participants on tirzepatide 15 mg lost roughly 47% more weight than those on semaglutide 2.4 mg on average; tirzepatide also showed superior results on the proportion of participants achieving ≥10%, ≥15%, and ≥20% body weight loss thresholds. For the specific percentages, check the published results in JAMA (Jastreboff et al., 2025) — figures can drift between versions.
The trial confirmed what cross-trial comparisons had long suggested: dual GLP-1/GIP agonism produces more weight loss than GLP-1 agonism alone.
Why the Mechanism Difference Matters
Semaglutide targets only the GLP-1 receptor: it suppresses appetite and slows gastric emptying. Tirzepatide adds the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a gut hormone involved in insulin secretion, fat metabolism, and energy regulation.
The combined activation appears to:
- Produce greater appetite suppression than GLP-1 alone
- Act directly on fat tissue through a pathway distinct from the central appetite effect
- Improve insulin sensitivity via a mechanism separate from GLP-1
The additive effect isn't fully understood at a mechanistic level. GIP was once thought to promote fat storage — which made tirzepatide's weight loss advantage surprising when it first emerged. The current thinking is that GIP receptor activation in the presence of GLP-1 signaling has different effects than either alone, and that the combination creates a synergistic metabolic response. It's one of the more genuinely interesting open questions in this drug class.
What the Numbers Mean Practically
| Drug | Class | Typical weight loss range (trials) |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | GLP-1 agonist | ~10–18% over 68 weeks |
| Tirzepatide 10–15 mg (Zepbound) | GLP-1 + GIP dual agonist | ~16–25% over 72 weeks |
These are ranges from trial populations, not guarantees. Individual response varies more than the averages suggest. Some people do better on Wegovy than others do on Zepbound. The comparison tells you what happens on average — it doesn't determine what will happen to you specifically.
At the individual level, other factors often dominate: insurance coverage, tolerability, whether you have type 2 diabetes, and whether you've tried one drug before.
When to Choose Semaglutide Instead
Despite the weight loss advantage, tirzepatide isn't always the better choice:
- Insurance coverage: Wegovy may be covered when Zepbound isn't, or vice versa. A gap of hundreds of dollars per month makes the choice easy for most people.
- Tolerability: Side effect profiles differ slightly between the two drugs. Some people tolerate semaglutide better; others find tirzepatide's nausea profile more manageable. The only way to know is to try.
- Type 2 diabetes: Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for T2D management. For people who need the glycemic benefit as the primary goal, either is reasonable — ask your prescriber which fits your profile.
- Already doing well on one drug: If you're responding well to Wegovy, switching to Zepbound for a theoretically better average isn't necessarily worth the disruption, restart dose, and re-titration.
The SURMOUNT-5 data establishes a population-level advantage for tirzepatide. Your individual situation may point in a different direction, and that's a reasonable place to land.
Can You Switch from Wegovy to Zepbound?
Yes, and it's increasingly common. The switch is generally manageable:
- Stop your current Wegovy dose.
- Wait one week (to let the overlap window pass).
- Start tirzepatide at the 2.5 mg starter dose — do not start at a dose equivalent to where you were on semaglutide. The drugs have different potency curves and skipping titration on tirzepatide typically backfires with nausea.
- Titrate through the standard schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, in 4-week increments.
Your clinician should guide the specific timing, especially if you had side effects on semaglutide that might predict tirzepatide tolerability.